You are here:

colesevelam hydrochloride (Cholestagel)


In the absence of a submission from the holder of the marketing authorisation

Colesevelam hydrochloride (Cholestagel), is not recommended for use within NHSScotland for the treatment of:

- primary hypercholesterolaemia, co-administered with an HMG-CoA reductase inhibitor (statin), as adjunctive therapy to diet to provide an additive reduction in LDL-cholesterol levels in patients not adequately controlled with a statin alone.

- as monotherapy as adjunctive therapy to diet for reduction of elevated total and LDL- cholesterol in patients with isolated primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: colesevelam hydrochloride (Cholestagel)
SMC Drug ID: 451/08
Manufacturer: Genzyme Therapeutics Ltd
Indication: primary hypercholesterolaemia
BNF Category:
Sub Category: 2.1 Positive inotropic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 11 February 2008